just out..13g statement of ownership.Seems funny that someone would buy just over 5% so that they would have to register with sec.good news is that outstanding shares are still around 49.2 million.GLTA.UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
ENTEST BIOMEDICAL, INC
(Name of Issuer)
Common Stock, par value $0.001
(Title of Class of Securities)
29383T102
(CUSIP Number)
January 26, 2018
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 29383T102
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Life Sciences Journeys, Inc. (82-3143794)
CITIZENSHIP OR PLACE OF ORGANIZATION
Wyoming, USA
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER
2,500,000
6.
SHARED VOTING POWER
2,500,000
7.
SOLE DISPOSITIVE POWER
2,500,000
8.
SHARED DISPOSITIVE POWER
2,500,000
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,500,000
10.
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ¨
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.08%
12.
TYPE OF REPORTING PERSON (see instructions) CO
Item 1.
(a)
Name of Issuer
Entest BioMedical Inc.
(b)
Address of Issuer’s Principal Executive Offices
4700 Spring St, Suite 304
La Mesa, CA
91942
Item 2. (a)
Name of Person Filing
Life Sciences Journeys, Inc
(b)
Address of the Principal Office or, if none, residence
109 East 17 th Street, Suite 25
Cheyenne, WY
82001
(c)
Citizenship
USA
(d)
Title of Class of Securities
Common stock, par value $0.001
(e)
CUSIP Number
29383T102
(k)
A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: N/A
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a)
Amount beneficially owned: 2,500,000
(b)
Percent of class: 5.08%
(c)
Number of shares as to which the person has:
(i)
Sole power to vote or to direct the vote: 2,500,000
(ii)
Shared power to vote or to direct the vote: 2,500,000
(iii)
Sole power to dispose or to direct the disposition of: 2,500,000
(iv)
Shared power to dispose or to direct the disposition of: 2,500,000
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨ .
Instruction . Dissolution of a group requires a response to this item.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
N/A
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
N/A
Item 8. Identification and Classification of Members of the Group.
N/A
Item 9. Notice of Dissolution of Group.
N/A
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: January 30, 2018 Life Sciences Journeys
By: /s/ Ivan DiTmars
Name: Ivan DiTmars
